Quotables
"During my service in the United States Congress, I took the initiative in creating the Internet."
Al Gore ; The basis for the later misquote by US Republicans that Gore had "invented" the Internet. Gore was the leading political champion of the modern-day Internet.
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 8188240 | Tab molecules The present invention relates to TAB molecules, ADEPT constructs directed against TAG-72, and their use in therapy. ... | 05/29/2012 |
| 8163887 | Use of immunoconjugates to enhance the efficacy of multi-stage cascade boosting vaccines Humoral and cellular immune responses against tumor cells and infectious agents are induced in a mammal using a vaccine comprising immunoconjugates that comprise antibodies and anti-idiotype antibodies that mimic an epitope of an antigen that is associated with a tu... | 04/24/2012 |
| 8143380 | Therapeutic peptides The invention relates to compounds that exhibit improved bioefficacy in multidose administration. More specifically, the invention relates to polypeptides or peptides modified to include an antibody Fc region and one or more water soluble polymers. ... | 03/27/2012 |
| 8129505 | Comb polymers The present invention provides a process for producing a comb polymer comprising the steps of: a) providing: (i) (w+z) molar equivalents of a monomer; (ii) one molar equivalent of an initiator compound of formula (IX), wherein B3 represents a halogen, B | 03/06/2012 |
| 8101728 | TAB molecules The present invention relates to TAB molecules, ADEPT constructs directed against TAG-72, and their use in therapy. ... | 01/24/2012 |
| 8022190 | Immuno-molecules containing viral proteins, compositions thereof and methods of using An immuno-molecule which comprises a soluble human MHC class I effector domain; and an antibody targeting domain which is linked to the soluble human MHC class I effector domain, methods of making same and uses thereof. ... | 09/20/2011 |
| 8008453 | Modified Fc molecules Disclosed is a process for preparing a pharmacologically active compound, in which at least one internal conjugation site of an Fc domain sequence is selected that is amenable to conjugation of an additional functional moiety by a defined conjugation chemistry throu... | 08/30/2011 |
| 7999083 | Immunoconjugates with an intracellularly-cleavable linkage The present invention relates to therapeutic conjugates with improved ability to target various diseased cells containing a targeting moiety (such as an antibody or antibody fragment), a linker and a therapeutic moiety, and further relates to processes for making an... | 08/16/2011 |
| 7989598 | Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates and methods of making said conjugates The present invention discloses a method for targeting maytansinoids to a selected cell population, the method comprising contacting a cell population or tissue suspected of containing the selected cell population with a cell-binding agent maytansinoid conjugate, wh... | 08/02/2011 |
| 7858759 | Anti-zB7H6 antibody-drug conjugates Disclosed is a newly identified B7 family member, zB7H6, which functions as a counter-receptor for the NK cell triggering receptor, NKp30. Methods and compositions for modulating NKp30-mediated NK cell activity based on the interaction of zB7H6 with NKp30, as well a... | 12/28/2010 |
| 7750128 | Modified Fc molecules The present invention concerns compositions of matter, for example, but not limited to, modified antibodies, in which one or more biologically active peptides are incorporated into a loop region of a non-terminal domain of an immunoglobulin Fc domain. ... | 07/06/2010 |
| 7750127 | Modified Fc molecules The present invention concerns compositions of matter, for example, but not limited to, modified antibodies, in which one or more biologically active peptides are incorporated into a loop region of a non-terminal domain of an immunoglobulin Fc domain. ... | 07/06/2010 |
| 7714113 | Fusion proteins of humanized g250 specific antibodies and uses thereof Chimeric antibodies, as well as fusion proteins which comprise chimeric antibodies, are disclosed. The antibodies bind to GM-CSF, CD-30, and G250 antigen. The fusion proteins include biologically active portions of tumor necrosis factor, or full length tumor necrosi... | 05/11/2010 |
| 7662931 | Modified Fc molecules The present invention concerns compositions of matter, for example, but not limited to, modified antibodies, in which one or more biologically active peptides are incorporated into a loop region of a non-terminal domain of an immunoglobulin Fc domain. ... | 02/16/2010 |
| 7655764 | Modified Fc molecules The present invention concerns compositions of matter, for example, but not limited to, modified antibodies, in which one or more biologically active peptides are incorporated into a loop region of a non-terminal domain of an immunoglobulin Fc domain. ... | 02/02/2010 |
| 7655765 | Modified Fc molecules The present invention concerns compositions of matter, for example, but not limited to, modified antibodies, in which one or more biologically active peptides are incorporated into a loop region of a non-terminal domain of an immunoglobulin Fc domain. ... | 02/02/2010 |
| 7645861 | Modified Fc molecules The present invention concerns compositions of matter, for example, but not limited to, modified antibodies, in which one or more biologically active peptides are incorporated into a loop region of a non-terminal domain of an immunoglobulin Fc domain. ... | 01/12/2010 |
| 7598353 | Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof Cancer treatments use a therapy that: 1) interferes with the interaction between CD200 and its receptor to block immune suppression thereby promoting eradication of the cancer cells; and 2) directly kills the cancer cells either by complement-mediated or antibody-de... | 10/06/2009 |
| 7442778 | Modified Fc molecules The present invention concerns molecules and a process in which one or more biologically active peptides are incorporated into an Fc domain. In this invention, pharmacologically active compounds may be prepared by a process comprising (a) selecting at least one pept... | 10/28/2008 |
| 7438908 | Anti-human tenascin monoclonal antibody A novel anti-human tenascin ST2146 monoclonal antibody is described endowed with high affinity with the native antigen and high tumor selectivity. The cST2146 hybridoma is stably producing the antibody in high density culture conditions and is suitable for the indus... | 10/21/2008 |
| 7429645 | Humanized anti-lymphotoxin beta receptor antibodies This invention concerns humanized antibodies specific for the lymphotoxin beta receptor (LT-β-R), cell lines that produce these antibodies, immunochemicals made from the antibodies, and diagnostic methods that use the antibodies. The invention also relates to the u... | 09/30/2008 |
| 7425328 | Tissue factor antibodies and uses thereof The present invention provides antibodies capable of binding to human tissue factor, which do not inhibit tissue factor mediated blood coagulation compared to a normal plasma control. Further described are methods of making and methods of using the antibodies of the... | 09/16/2008 |
| 7423127 | Antibodies to a polypeptide encoded by a nucleic acid overexpressed in melanoma The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of ... | 09/09/2008 |
| 7420040 | Cytotoxicity mediation of cells evidencing surface expression of TROP-2 The present invention relates to a method for producing cancerous disease modifying antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production of... | 09/02/2008 |
| 7420039 | Individualized anti-cancer antibodies The present invention relates to a method for producing patient specific anti-cancer antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production o... | 09/02/2008 |
| 7420041 | Cytotoxicity mediation of cells evidencing surface expression of TROP-2 The present invention relates to a method for producing cancerous disease modifying antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production of... | 09/02/2008 |
| 7408040 | Antibodies to PDGF-D PDGF-D, a new member of the PDGF/VEGF family of growth factors, as well as the nucleotide sequence encoding it, methods for producing it, antibodies and other antagonists to it, transfected and transformed host cells expressing it, pharmaceutical compositions contai... | 08/05/2008 |
| 7404956 | Immunoglobulin chimeric monomer-dimer hybrids The invention relates to a chimeric monomer-dimer hybrid protein wherein said protein comprises a first and a second polypeptide chain, said first polypeptide chain comprising at least a portion of an immunoglobulin constant region and a biologically active molecule... | 07/29/2008 |
| 7393531 | Cytotoxicity mediation of cells evidencing surface expression of MCSP This invention relates to the diagnosis and treatment of cancerous diseases, particularly to the mediation of cytotoxicity of tumor cells; and most particularly to the use of cancerous disease modifying antibodies (CDMAB), optionally in combination with one or more ... | 07/01/2008 |
| 7393684 | Immunoconjugates of anti-IL-20 antibodies and hybridoma cell lines expressing anti-IL-20 antibodies The present invention relates to blocking the activity of IL-20 polypeptide molecules. IL-20 is a cytokine that is involved in inflammatory processes and human disease. IL-20RA/IL-20RB is a common receptor for IL-20. The present invention includes anti-IL-20 antibod... | 07/01/2008 |
| 7390885 | Humanized collagen antibodies and related methods The invention provides a grafted antibody, or functional fragment thereof, comprising one or more complementarity determining regions (CDRs) having at least one amino acid substitution in one or more CDRs of a heavy chain CDR, where the grafted antibody or functiona... | 06/24/2008 |
| 7387772 | Chimeric, human and humanized anti-CSAP monoclonal antibodies The present invention provides humanized, chimeric and human anti-CSAp antibodies and anti-CSAp antibody fusion proteins that are useful for the treatment and diagnosis of various cancers, including colon cancer. ... | 06/17/2008 |
| 7387776 | Human monoclonal antibodies against CD30 Isolated human monoclonal antibodies which bind to CD30 (e.g., human CD30) are disclosed. The human antibodies can be produced in a non-human transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by underg... | 06/17/2008 |
| 7378094 | Therapeutic uses of complement receptor 2 The present invention is directed to an immune complex composition, and a method of using that complex to enhance an in viva immune response against a preselected target antigen. The immune complexes of the present invention comprise a monoclonal antibody specific f... | 05/27/2008 |
| 7378091 | Antibodies against carbonic anhydrase IX (CA IX) tumor antigen The present invention relates generally to the generation and characterization of anti-CA IX monoclonal antibodies. The invention further relates to the use of such anti-CA IX antibodies in the diagnosis and treatment of disorders associated with increased activity ... | 05/27/2008 |
| 7371723 | Therapeutic agents comprising pro-apoptotic proteins The present invention relates to targeted killing of a cell utilizing a chimeric polypeptide comprising a cell-specific targeting moiety and a signal transduction pathway factor. In a preferred embodiment, the signal transduction pathway factor is an apoptosis-induc... | 05/13/2008 |
| 7364736 | Antibodies to OPGL Antibodies that interact with osteoprotegerin ligand (OPGL) are described. Methods of treating osteopenic disorders by administering a pharmaceutically effective amount of antibodies to OPGL are described. Methods of detecting the amount of OPGL in a sample using an... | 04/29/2008 |
| 7365167 | Humanized collagen antibodies and related methods The invention provides a grafted antibody, or functional fragment thereof, comprising one or more complementarity determining regions (CDRs) having at least one amino acid substitution in one or more CDRs of a heavy chain CDR, where the grafted antibody or functiona... | 04/29/2008 |
| 7361347 | Cytotoxic CD44 antibody immunoconjugates The invention relates to novel conjugates of CD44 antibodies with cytotoxic compounds, pharmaceutical compositions comprising such compounds, and their use in tumor therapy. ... | 04/22/2008 |
| 7361343 | Cytotoxicity mediation of cells evidencing surface expression of CD63 This invention relates to the diagnosis and treatment of cancerous diseases, particularly to the mediation of cytotoxicity of tumor cells; and most particularly to the use of cancerous disease modifying antibodies (CDMAB), optionally in combination with one or more ... | 04/22/2008 |
